To save patient lives where targeted delivery of nitric oxide is vital.


To become a world leading provider of nitric oxide delivering drugs.

Attgeno’s objective is to be the first company to bring the third generation of nitric oxide (NO) delivery products into clinical use to be able to target specific organs and thereby avoiding NO related side effects in other parts of the body. One condition where a lack of NO is of importance is acute pulmonary hypertension, which is high blood pressure in vessels of the lung blood circulation. It is a life-threatening condition that occurs in many different critical illnesses and contributes to the loss of hundreds of thousands of lives each year. Supernitro aspires to be the first line of treatment for acute pulmonary hypertension, regardless of its underlying cause.